The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.



Latest Headlines

Latest Headlines

Is Pfizer's CEO as bold as promised?

Like natives encountering a strange explorer in an old B movie, investors hailed Jeffrey Kindler (photo) when he was

Supremes vote 4-4 in pre-emption suit

The Supreme Court came and saw and voted but left no clarity on pre-emption behind. Because Chief Justice John Roberts sat out the case, the vote ended in a 4-4 tie, automatically affirming the lower

SPOTLIGHT: Is Pfizer's CEO as bold as promised?

Like natives encountering a strange explorer in an old B movie, investors hailed Jeffrey Kindler (photo) when he was picked to succeed Pfizer CEO

Pfizer snaps up Serenex in buyout

Pfizer has beefed up its prospects in the cancer arena with today's buyout of Durham, NC-based Serenex. The biotech has been developing drugs for tumors and cancers of the blood and bone marrow....

Celebs lose cachet as drug marketers

Celebs may help sell magazines but do they really help market drugs? In the wake of

Bayer lower 2008 expectations

Call it Bad News Bayer. The German company reported a whopping 78 percent drop in profits for the fourth quarter and forecast 2008 sales growth at its lowest level in years. Though 2007 full-year

SPOTLIGHT: Jarvik defends his heart-doc credentials

The star of Pfizer's canceled Lipitor campaign speaks out: "My credibility as a heart expert is fully justified and is fairly represented" in the ads, Dr. Robert Jarvik said in a statement. Plus, he

Pfizer yanks Lipitor ads starring Jarvik

All right, already, Pfizer says. The drugmaker is pulling its Lipitor ads that feature artificial heart inventor Robert Jarvik. That's after a flurry of media coverage--in which Jarvik was shown to

Pfizer snags Encysive in $195M buyout

Pfizer has demonstrated once again just how interested it is in biotech with its $195

SPOTLIGHT: Chantix scrips drop 5% on FDA alert

Prescriptions for Pfizer's stop-smoking drug Chantix dropped 5 percent last week after the FDA called it "